Connor Clark & Lunn Investment Management Ltd. Acquires 29,295 Shares of Emergent Biosolutions Inc. (NYSE:EBS)

Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 3.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 931,627 shares of the biopharmaceutical company's stock after buying an additional 29,295 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 1.71% of Emergent Biosolutions worth $4,528,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Alberta Investment Management Corp purchased a new position in Emergent Biosolutions during the first quarter worth about $458,000. XTX Topco Ltd purchased a new position in Emergent Biosolutions during the first quarter worth about $417,000. Corton Capital Inc. purchased a new position in Emergent Biosolutions during the first quarter worth about $70,000. Prescott Group Capital Management L.L.C. boosted its holdings in Emergent Biosolutions by 198.9% during the first quarter. Prescott Group Capital Management L.L.C. now owns 627,671 shares of the biopharmaceutical company's stock worth $3,050,000 after purchasing an additional 417,671 shares during the last quarter. Finally, Cetera Investment Advisers boosted its holdings in Emergent Biosolutions by 28.5% during the first quarter. Cetera Investment Advisers now owns 356,281 shares of the biopharmaceutical company's stock worth $1,732,000 after purchasing an additional 79,034 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut shares of Emergent Biosolutions from a "buy" rating to a "hold" rating in a report on Saturday, August 9th.

Emergent Biosolutions Stock Up 0.3%

Emergent Biosolutions stock traded up $0.03 during midday trading on Friday, hitting $8.85. 1,117,257 shares of the stock were exchanged, compared to its average volume of 1,432,847. Emergent Biosolutions Inc. has a 52-week low of $4.02 and a 52-week high of $13.28. The stock has a market capitalization of $472.15 million, a price-to-earnings ratio of 3.61 and a beta of 1.97. The business's 50-day moving average price is $6.96 and its 200-day moving average price is $6.57. The company has a quick ratio of 3.00, a current ratio of 5.66 and a debt-to-equity ratio of 1.25.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, topping the consensus estimate of ($0.26) by $0.42. The business had revenue of $140.90 million for the quarter, compared to analyst estimates of $148.55 million. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.63%. On average, research analysts expect that Emergent Biosolutions Inc. will post -0.63 EPS for the current fiscal year.

Insider Activity

In other Emergent Biosolutions news, Director Keith Katkin sold 7,844 shares of Emergent Biosolutions stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $6.30, for a total value of $49,417.20. Following the sale, the director owned 86,431 shares of the company's stock, valued at approximately $544,515.30. The trade was a 8.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Donald W. Degolyer sold 7,844 shares of Emergent Biosolutions stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $8.65, for a total transaction of $67,850.60. Following the completion of the sale, the director directly owned 137,659 shares in the company, valued at approximately $1,190,750.35. This represents a 5.39% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.20% of the company's stock.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.